Literature DB >> 12084425

Symptom patterns and subgrouping of schizophrenic patients: significance of negative symptoms assessed on admission.

Hai-Gwo Hwu1, Chun-Houh Chen, Tzung-Jeng Hwang, Chih-Min Liu, Joseph J Cheng, Shi-Kwang Lin, Shi-Kai Liu, Chen-Hsin Chen, Yueh-Yun Chi, Chih-Wen Ou-Young, Hsin-Nan Lin, Wei J Chen.   

Abstract

This study subgroups schizophrenic patients based on symptoms assessed on admission and examines the validity of the subgrouping using follow-up data and other clinical outcome variables. Schizophrenic patients (n=163) from consecutive admission received ratings on the positive and negative syndrome scale (PANSS) on admission and during a 1-year follow-up course. An exploratory graphic analysis on the admission PANSS derived four symptom dimensions: negative symptoms, disorganized thought, hostility/excitement and delusions/hallucinations. This yielded two subgroups of patients on admission, a group with marked negative (GWNEG) and a group without marked negative (GONEG) symptoms. Compared with the GONEG, the GWNEG had a poorer recovery rate, more impairment in attention, a slower response of the delusion/hallucination symptoms to neuroleptic treatment and a longer duration of index hospitalization. At a one-year follow-up, the GWNEG assessed on admission had persistently higher scores on the negative symptom and disorganized thought syndromes, less relapse rate, a shorter duration on job, as well as worse social functioning than the GONEG. Thus, the GONEG might comprise patients having a pure paranoid syndrome with quick and better treatment response, while the GWNEG comprises patients with the blunt-disorganization syndrome having a poorer outcome.

Entities:  

Mesh:

Year:  2002        PMID: 12084425     DOI: 10.1016/s0920-9964(01)00251-1

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  9 in total

1.  Genetic associations and expression of extra-short isoforms of disrupted-in-schizophrenia 1 in a neurocognitive subgroup of schizophrenia.

Authors:  Chih-Min Liu; Yu-Li Liu; Hai-Gwo Hwu; Cathy Shen-Jang Fann; Ueng-Cheng Yang; Pei-Chun Hsu; Chien-Ching Chang; Wei J Chen; Tzung-Jeng Hwang; Ming H Hsieh; Chen-Chung Liu; Yi-Ling Chien; Yi-Tin Lin; Ming T Tsuang
Journal:  J Hum Genet       Date:  2019-04-11       Impact factor: 3.172

2.  Effects of risperidone and quetiapine on cognition in patients with schizophrenia and predominantly negative symptoms.

Authors:  Michael Riedel; Ilja Spellmann; Martin Strassnig; Anette Douhet; Sandra Dehning; Markus Opgen-Rhein; Rosamaria Valdevit; Rolf R Engel; Nikolaus Kleindienst; Norbert Müller; Hans-Jürgen Möller
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2007-07-14       Impact factor: 5.270

3.  Haplotypes of the D-Amino Acid Oxidase Gene Are Significantly Associated with Schizophrenia and Its Neurocognitive Deficits.

Authors:  Yu-Li Liu; Sheng-Chang Wang; Hai-Gwo Hwu; Cathy Shen-Jang Fann; Ueng-Cheng Yang; Wei-Chih Yang; Pei-Chun Hsu; Chien-Ching Chang; Chun-Chiang Wen; Jyy-Jih Tsai-Wu; Tzung-Jeng Hwang; Ming H Hsieh; Chen-Chung Liu; Yi-Ling Chien; Chiu-Ping Fang; Stephen V Faraone; Ming T Tsuang; Wei J Chen; Chih-Min Liu
Journal:  PLoS One       Date:  2016-03-17       Impact factor: 3.240

4.  Validation of the cognitively normal range and below normal range subtypes in chronically hospitalized patients with schizophrenia.

Authors:  Shih-Kuang Chiang; Ching-Huan Ni; Chih-Pu Tsai; Keng-Chang Lin
Journal:  Schizophr Res Cogn       Date:  2016-07-13

5.  Aripiprazole Once-Monthly in the Treatment of Acute Psychotic Episodes in Schizophrenia: Post Hoc Analysis of Positive and Negative Syndrome Scale Marder Factor Scores.

Authors:  Zahinoor Ismail; Timothy Peters-Strickland; Maia Miguelez; Ross A Baker; Peter Hertel; Anna Eramo; Na Jin; Pamela Perry; Raymond Sanchez; Robert D McQuade; John M Kane
Journal:  J Clin Psychopharmacol       Date:  2017-06       Impact factor: 3.153

6.  The DAO gene is associated with schizophrenia and interacts with other genes in the Taiwan Han Chinese population.

Authors:  Hsin-Chou Yang; Chih-Min Liu; Yu-Li Liu; Chia-Wei Chen; Chien Ching Chang; Cathy S J Fann; Jen-Jie Chiou; Ueng-Cheng Yang; Chun-Houh Chen; Stephen V Faraone; Ming T Tsuang; Hai-Gwo Hwu
Journal:  PLoS One       Date:  2013-03-28       Impact factor: 3.240

7.  A comparison of olanzapine and risperidone on the risk of psychiatric hospitalization in the naturalistic treatment of patients with schizophrenia.

Authors:  Haya Ascher-Svanum; Baojin Zhu; Douglas Faries; Frank R Ernst
Journal:  Ann Gen Hosp Psychiatry       Date:  2004-06-02

8.  Staging of Schizophrenia With the Use of PANSS: An International Multi-Center Study.

Authors:  Konstantinos N Fountoulakis; Elena Dragioti; Antonis T Theofilidis; Tobias Wikilund; Xenofon Atmatzidis; Ioannis Nimatoudis; Erik Thys; Martien Wampers; Luchezar Hranov; Trayana Hristova; Daniil Aptalidis; Roumen Milev; Felicia Iftene; Filip Spaniel; Pavel Knytl; Petra Furstova; Tiina From; Henry Karlsson; Maija Walta; Raimo K R Salokangas; Jean-Michel Azorin; Justine Bouniard; Julie Montant; Georg Juckel; Ida S Haussleiter; Athanasios Douzenis; Ioannis Michopoulos; Panagiotis Ferentinos; Nikolaos Smyrnis; Leonidas Mantonakis; Zsófia Nemes; Xenia Gonda; Dora Vajda; Anita Juhasz; Amresh Shrivastava; John Waddington; Maurizio Pompili; Anna Comparelli; Valentina Corigliano; Elmars Rancans; Alvydas Navickas; Jan Hilbig; Laurynas Bukelskis; Lidija Injac Stevovic; Sanja Vodopic; Oluyomi Esan; Oluremi Oladele; Christopher Osunbote; Janusz Κ Rybakowski; Pawel Wojciak; Klaudia Domowicz; Maria Luisa Figueira; Ludgero Linhares; Joana Crawford; Anca-Livia Panfil; Daria Smirnova; Olga Izmailova; Dusica Lecic-Tosevski; Henk Temmingh; Fleur Howells; Julio Bobes; Maria Paz Garcia-Portilla; Leticia García-Alvarez; Gamze Erzin; Hasan Karadağ; Avinash De Sousa; Anuja Bendre; Cyril Hoschl; Cristina Bredicean; Ion Papava; Olivera Vukovic; Bojana Pejuskovic; Vincent Russell; Loukas Athanasiadis; Anastasia Konsta; Dan Stein; Michael Berk; Olivia Dean; Rajiv Tandon; Siegfried Kasper; Marc De Hert
Journal:  Int J Neuropsychopharmacol       Date:  2019-11-01       Impact factor: 5.176

9.  Identifying dopamine supersensitivity through a randomized controlled study of switching to aripiprazole from other antipsychotic agents in patients with schizophrenia.

Authors:  Chia-Hao Ma; Hung-Yu Chan; Ming H Hsieh; Chen-Chung Liu; Chih-Min Liu; Hai-Gwo Hwu; Ching-Hua Kuo; Wei J Chen; Tzung-Jeng Hwang
Journal:  Ther Adv Psychopharmacol       Date:  2022-01-28
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.